New data for Roche’s Evrysdi (risdiplam) demonstrate long-term efficacy and safety in a broad population of people with spinal muscular atrophy (SMA)

Roche has published their latest interim results from the RAINBOWFISH study  in pre-symptomatic babies with SMA under two months of age, which demonstrated its safety and efficacy in treating pre-symptomatic babies under two months of age with SMA.